Participation in external quality assessment (EQA) is a key element of quality assurance in medical laboratories. In genetics EQA, both genotyping and interpretation are assessed. We aimed to analyse changes in the completeness of interpretation in clinical laboratory reports of the European cystic fibrosis EQA scheme and to investigate the effect of the number of previous participations, laboratory accreditation/certification status, setting and test volume. We distributed similar versions of mock clinical cases to eliminate the influence of the difficulty of the clinical question on interpretation performance: a cystic fibrosis patient (case 1) and a cystic fibrosis carrier (case 2). We then performed a retrospective longitudinal study of reports over a 6-year period from 298 participants for case 1 (2004, 2008, 2009) and from 263 participants for case 2 (2006, 2008, 2009). The number of previous participations had a positive effect on the interpretation score (Po0.0001), whereas the laboratory accreditation/certification status, setting and test volume had no effect. Completeness of interpretation improved over time. The presence of the interpretation element 'requirement for studying the parents to qualify the genotype' increased most (from 49% in 2004 to 93% in 2009). We still observed room for improvement for elements that concerned offering testing for familial mutations in relatives and prenatal/preimplantation diagnosis (16% and 24% omission, respectively, for case 1 in 2009). Overall, regular participation in external quality assessment contributes to improved interpretation in reports, with potential value for quality of care for patients and families by healthcare professionals involved in genetic testing.
INTRODUCTION
Constitutional genetic information is constant throughout life; patients are typically tested once in their lifetime and the test may never be repeated or confirmed. Consequently, incorrect results may not become apparent for years and can lead to harmful outcomes for patients and family members, such as unnecessary surgery or prenatal diagnosis, or erroneous carrier testing. Given the complex and sensitive nature of genetic information, testing services have the responsibility to accurately test and interpret genetic results in the context of the clinical indication and family history, while taking into account that the recipient of the laboratory report may not have genetic expertise.
In the 1990s, a system known as external quality assessment (EQA, in Europe) or proficiency testing (PT, in the United States) was introduced in molecular genetic diagnostic laboratories to evaluate the ability to accurately determine genotypes and to assess the accuracy and completeness of the interpretation of the test results. 1 Independent assessment of test performance is a recommendation of the Organisation for Economic Cooperation and Development, and a requirement for laboratory accreditation to the International Organisation for Standardisation (ISO) 15 189 and 17 025 standards and for complying with the US Clinical Laboratory Improvement Amendments (CLIA). [2] [3] [4] [5] One of the main European EQA providers in molecular genetics is the Cystic Fibrosis Network, which has been organising an EQA scheme for cystic fibrosis (CF; OMIM no. 219700) since 1996. 6 Assessment of reports through the Cystic Fibrosis Network and other disease-specific schemes organised by the European Molecular Genetics Quality Network revealed that there is room for improvement of the interpretation in laboratory reports. For example, the EQA scheme for molecular diagnosis of hereditary recurrent fevers described that only 8-47% of the reports mentioned interpretation of testing results (15-50 participants, 2006-2008) . 7 Similarly, the spinocerebellar ataxias EQA scheme reported average interpretation scores of 1.53/2.00 and 1.76/2.00 (26-37 participants, 2005-2006) and the scheme for mutation detection in the breast cancer genes revealed average interpretation scores from 1.46/2.00 to 1.78/2.00 (25-41 participants, [2000] [2001] [2002] . 8, 9 The maximum interpretation score in these schemes was 2.0 per laboratory; the average interpretation scores represented the average of interpretation scores of all participating laboratories in a certain year.
Although EQA is accepted as a corner stone of quality assurance, direct evidence that participation in EQA leads to improved interpretation is lacking because measuring improvement of interpretation is challenging. 10, 11 First, interpretation depends heavily on the complexity of the mock clinical cases, which change every year. 12 Second, published interpretation scores represent the mean annual score for the whole group of participants, whose members vary from year to year, with a mix of regular, irregular and new participants.
This large retrospective longitudinal study was performed through the Cystic Fibrosis Network over a 6-year period among more than 300 laboratories. We examined and analysed changes in the completeness of interpretation in clinical laboratory reports when similar versions of mock clinical cases were distributed and thus when the influence of the complexity of the clinical question was eliminated. In addition, we investigated the effect of the number of previous EQA participations on the completeness of the interpretation and thus evaluated the efficacy of EQA. Monitoring and improving the completeness of interpretation in clinical reports is essential as it will lead to better quality of care for patients and families.
MATERIALS AND METHODS

Context and setting of the study
In a standard CF EQA round (which takes 1 year, starting from autumn until summer the year after), a set of samples (purified DNA) and mock cases for closely related clinical situations are sent for analysis to voluntarily registered laboratories. Laboratory reports submitted by the participants to the EQA provider should reflect routine reports issued to requesting physicians. The assessors determine the key interpretation elements that should be present in participants' laboratory reports before dispatching the samples. Their decisions are based on expert consensus and best practice guidelines, and depend on the clinical indication in the case. [13] [14] [15] [16] Two assessors independently evaluate genotypes and interpretation in the submitted reports. Results are also discussed during an assessment meeting. Apart from laboratory reports, the CF Network requests information on the accreditation and certification status of the laboratory, the laboratory setting (eg, hospital, university, industry) and the number of CF samples tested per year (laboratory test volume). At the end of the EQA round, participants receive feedback in the form of laboratory-specific individual comments and a general report addressed to all participants. Laboratory information and performance data have been stored systematically in a database since 2004, using a unique identification code for each laboratory. Table 1 ). The genotypes were chosen not to affect the evaluation. The laboratories were not informed about the similarity of the cases, nor that we were conducting this study.
Study design
The interpretation elements evaluated in the clinical laboratory reports for both cases in the study are outlined in Table 2 . A laboratory received marks when an interpretation element was present and correct in the report, or when an element was present but not clearly defined (eg, a laboratory recommends genetic counselling without specifying whom it may concern). No marks were awarded when the element was absent or if the element was present, but wrong (eg, a wrong risk figure) . The sum of the marks (further referred to as the 'interpretation score') is maximum 2.0 per case.
We collected the stored performance data for these specific similar cases only at the end of the 6-year period and then conducted a longitudinal retrospective analysis. If participants provided laboratory information (accreditation/certification status, setting and test volume) in different years, only the most recently submitted information was used in this study.
Laboratories that registered for the EQA scheme but did not submit laboratory reports were not taken into account in the study ( 
Statistical analysis
The interpretation score for a laboratory comprised values between 0.0 and 2.0 with nine possible levels. Given the very skew distribution of the score (higher scores are more frequent), we adopted a proportional odds model (odds ratios (OR) and 95% confidence intervals (CI)) to analyse the effect of the number of previous EQA participations, the effect of the year, the laboratory accreditation/certification status, setting and test volume. The proportional odds model considered the interpretation score as an ordered category response and modelled the probability that the response fell within the higher categories (equivalent to a higher score) versus the lower categories (lower score). A P-value o0.05 was considered significant. Generalised estimating equations were used for estimation to account for clustering of observations coming from the same laboratory.
The specific interpretation elements on which the laboratory reports were evaluated were given a binary score (0/1; element absent or element wrong/ element present and correct or present but not clearly defined). The effect of the number of previous participations on the success probability on each aspect were analysed using a logistic regression model and using generalised estimating equations to take into account the clustering of the scores due to the longitudinal data structure.
All analyses have been performed using SAS software, version 9.2 of the SAS System for Windows (SAS Institute Inc., Cary, NC, USA).
RESULTS
Study population
Data regarding the characteristics of the 311 laboratories (272 European), from 39 different countries included in the study are described in Table 3 .
All these laboratories offered testing for cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations as a clinical test. Trend of the mean annual interpretation score First, we calculated the mean annual interpretation score for the whole group of participants for both cases (black rounds in Figure 1 ). In general, scores improved over the years. A significant difference was found between the two cases with better interpretation scores for case 1 (P ¼ 0. we observed a positive effect of the number of previous participations on the presence of all specific interpretation elements, except for 'confirmation of the CF carrier status' (P ¼ 0.47) in case 2 ( Table 4) .
Effect of the laboratory accreditation or certification status, setting and test volume on the interpretation
We evaluated whether laboratories that were accredited or certified had more complete interpretation than those that were not accredited or certified. In addition, we evaluated whether a certain setting was associated with better interpretation and whether laboratories that test more CF samples per year had better scores than those that test fewer samples per year. No effect was observed of the laboratories' accreditation/certification status on the interpretation scores (P ¼ 0.18 for case 1, P ¼ 0.27 for case 2). However, within the group of accredited and certified laboratories, there was an effect of the number of years since the accreditation or certification. We found lower scores for laboratories that had been accredited or certified for a longer time for case 1 (P ¼ 0. 
DISCUSSION
Principal findings
First, this study with similar mock clinical cases revealed that regular participation in EQA leads to a more complete interpretation in laboratory reports. Our observations support the view that EQA participation is a form of continuous education, whereby a comprehensive EQA general report and individual comments contribute to the improvement observed. Interpretation could additionally be influenced by external factors such as the availability of best practice guidelines and publications. [13] [14] [15] Second, the presence in clinical reports of all investigated interpretation elements improved over the years. Two elements increased remarkably more (430%) than others: stating the need to test the parents of a CF patient to confirm homozygosity or compound heterozygosity (need for qualification of the genotype) and Interpretation in CF laboratory reports S Berwouts et al mentioning the possibility of testing the relatives. The fact that most laboratories currently mention that genotypes must be confirmed represents an important improvement in laboratory practice and a reduced probability of error or misinterpretation, and shows that laboratories better understand the limitations of genetic analysis, especially PCR-based tests. Third, although all investigated interpretation elements were included in the majority (480%) of reports by the end of the study, there was room for improvement for those aspects that concern offering testing for familial mutations in relatives or future pregnancies. The possibility of testing relatives should be mentioned in all cases in which an individual is positive for a CF-causing mutation. It is also recommended that laboratories mention the possibility of offering prenatal diagnosis for future pregnancies in all cases where a child was born with CF, as the risk of a future child with CF is one-fourth in each pregnancy. Opportunities for improvement were noticed more for case 2 than for case 1. This may be because laboratories interpret test results of patients with CF more assiduously than results of CF carriers. Nevertheless, in either case, genetic test reports can be referred to at a later date for relatives and future generations, and both situations must therefore be treated with the same assiduity.
Finally, no effect was observed of the laboratory accreditation/ certification status on the completeness of the interpretation. Laboratories that are not accredited, but that perform EQA, reach an equal quality of their clinical reports compared with accredited or certified laboratories, confirming EQA participation as a fundamental element of laboratory quality assurance. The reason why recently accredited/ certified (accredited) laboratories performed significantly better compared with those with more years of accreditation/certification (accreditation) is unclear. There might be a chance that recently accredited laboratories pay more attention to the improvement of their reports as they still have regular audits, whereas laboratories that have their quality management system in place for a long time, may become complacent. They perhaps just maintain their systems, with less attention to major adaptations.
Strengths and limitations
Our study has several important strengths. First, this is the largest longitudinal expert peer review of interpretation in genetic reporting for a single disorder. We were able to take advantage of the unique opportunity of having a large number of laboratories involved, from Europe, the United States and Australasia, principally because CF is a very commonly tested disorder compared with other genetic diseases. To evaluate the proportion of CFTR-testing laboratories in this study, we consulted Orphanet and estimated that 75% (272/361) of listed CFTR-testing laboratories were included in our study. 17 Second, this is the first study that intended to overcome the influence of the difficulty of the clinical case on the interpretation score by including similar cases over a relatively long period. Further, difference in interpretation scores were analysed statistically. Published results of other EQA schemes have mainly included data from EQA pilot years, without any statistical evidence that the interpretation improved. [7] [8] [9] It is known that assessment criteria and procedures are being set up in the pilot years and this could have a considerable impact on the trend of the interpretation score. In comparison, the CF EQA scheme was set up 8 years before this study and with a fixed group of assessors over the years.
Although this study provides important data on the impact of the number of previous participations on the interpretation in laboratory reports, it has potential limitations. Firstly, only reports for the EQA scheme were evaluated, and it is not possible to judge whether the laboratories' real practice has improved, or if tailored reports are prepared to 'satisfy' the EQA provider' . Secondly, although we have eliminated the influence of the variety of the clinical question, there might be a variety in the strictness of assessment. Even though the assessors group did not change over the years, it is likely that assessment was stricter year after year, thus reducing interpretation scores at later years. There might be a chance that the group of laboratories that participated only one time during the investigated period experienced a greater effect of the increase of strictness, compared with those that participated more times (cfr. decrease of the mean annual interpretation score in Figure 1 for the group that participated one time). Further, the data on laboratory accreditation/ certification status were provided by the laboratories themselves. We know from experience within the European project EuroGentest that misunderstanding about the exact meaning of accreditation is common and we cannot rule out that some laboratories claimed to be accredited, but meant licensed, or mistook hospital accreditation for laboratory accreditation and thus overestimated their status. 18, 19 The outcome with regard to the accreditation and certification status could have been different if the information given by the laboratories was 100% correct. Seen the fact that the accurateness of the data could not be guaranteed, we decided not to perform detailed research on the accreditation/certification status data. We thus did not analyse for instance whether or not the effect of accreditation/certification status on the interpretation score is generalisable to all accreditation and certification programs.
CONCLUSION AND IMPLICATIONS
A genetic test result differs from other diagnostic results in that it can have far-reaching effects on patients' and their relatives' life plans; furthermore, genetic tests are usually performed only once in a lifetime. Consequently it is of utmost importance that the result is correct and accompanied with an unambiguous, accurate and complete interpretation. We demonstrate that regular participation in EQA contributes to a more complete interpretation in laboratory test reports. Unfortunately, 50% of the CF EQA participants still do not participate regularly in the CF EQA scheme. In addition, based on data from Orphanet, at least 25% of the European CFTR-testing laboratories do not participate in the CF EQA scheme at all. Some of these are likely to participate in national CF EQA schemes organised by UKNEQAS, IEQA-ISS, Afssaps or INSTAND (only for c.1521_1523delCTT). [20] [21] [22] [23] We expect similar percentages in schemes for other disorders or methods. It seems likely that laboratories that do not participate in EQA and whose reports have never been objectively assessed by peers and against expert opinions would have relatively low interpretation scores, comparable to those that have participated in only 1 of the 3 investigated years (between 1.2/2.0 and 1.7/2.0). Therefore, participation of laboratories in EQA on a regular basis, for all disorders they test for, needs to be continuously encouraged. The adoption of ISO 15 189, for implementing a quality management system and assessing technical competence, in national legislations could accelerate the implementation of accreditation, and thus assure EQA participation in genetic testing laboratories. Today, this is the case in only a few European countries, for example in France where accreditation will be mandatory by 2016 for medical biological laboratories, and in Switzerland where EQA participation for all genetic tests is becoming mandatory. 24, 25 In the United States, the situation is different and all laboratories conducting moderate and/or high complexity testing are required by law (CLIA) to participate in PT for certain tests they perform. However, the CLIA regulations do not have PT requirements specific for molecular genetic tests. Therefore, laboratories that perform genetic tests must comply with the general requirements for alternative performance assessment for any test or analyte not specified as a regulated analyte to verify the accuracy of any genetic test or procedure they perform. 26 Unfortunately in the United States, focus is mainly on the assessment of the accuracy of the test result (genotyping) and not on interpretation assessment, which is sufficient to comply with CLIA. 5 We conclude that EQA contributes to improved interpretation of sensitive genetic test results and improved interpretation will lead to better quality of care for patients and their families by all healthcare professionals involved in and collaborating with genetic testing services.
